TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms

Ähnliche Einträge

• Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents
  von: Suzuki, Kazunori, et al.
  Veröffentlicht: (2017)
• TAK‐063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia
  von: Suzuki, Kazunori, et al.
  Veröffentlicht: (2018)
• S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS
  von: Suzuki, Kazunori, et al.
  Veröffentlicht: (2018)
• Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor
  von: Harada, Akina, et al.
  Veröffentlicht: (2015)
• Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
  von: Macek, Thomas A, et al.
  Veröffentlicht: (2020)